Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin

Internal Medicine

Volumn 52, Issue 10, 2013, Pages 1111-1114

  Nishijima, Yu ^a,b   Hirata, Haruhiko ^a   Himeno, Aiko ^b   Kida, Hiroshi ^a   Matsumoto, Masanori ^c   Takahashi, Ryo ^a   Otani, Yasushi ^a   Inoue, Kouji ^a   Nagatomo, Izumi ^a   Takeda, Yoshito ^a   Kijima, Takashi ^a   Tachibana, Isao ^a   Fujimura, Yoshihiro ^c   Kumanogoh, Atsushi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY HOSPITAL   (Japan)

^c NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Bevacizumab; Gemcitabine; Recombinant human soluble thrombomodulin; Thrombotic thrombocytopenic purpura

Indexed keywords

AZOSEMIDE; BEVACIZUMAB; CANDESARTAN HEXETIL; CISPLATIN; DISINTEGRIN; DOCETAXEL; DOXAZOSIN MESYLATE; ERLOTINIB; FRESH FROZEN PLASMA; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; METALLOPROTEINASE; NAVELBINE; NIFEDIPINE; PEMETREXED; RECOMBINANT SOLUBLE THROMBOMODULIN; RECOMBINANT THROMBOMODULIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ARTICLE; BLOOD CLOTTING TEST; BLURRED VISION; CASE REPORT; DRUG INDUCED DISEASE; FEMALE; FEVER; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; INTRAVASCULAR HEMOLYSIS; JAUNDICE; KIDNEY FUNCTION; LUNG CANCER; MULTIPLE CYCLE TREATMENT; PLEURA EFFUSION; THROMBOCYTE TRANSFUSION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ACUTE KIDNEY INJURY; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIHYPERTENSIVE AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; GLUTAMATES; GUANINE; HUMANS; HYPERTENSION; LUNG NEOPLASMS; MIDDLE AGED; OXONIC ACID; PLASMA; PURPURA, THROMBOTIC THROMBOCYTOPENIC; PYRIDINES; QUINAZOLINES; RECOMBINANT PROTEINS; SOLUBILITY; TAXOIDS; TEGAFUR; THROMBOMODULIN;

EID: 84877869518     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.52.9180     Document Type: Article

References (17)

1. Nguyen TC, Carcillo JA. Bench-to-bedside review: thrombocytopenia-associated multiple organ failure: a newly appreciated syndrome in the critically ill. Crit Care 10: 235, 2006.
2. Blake-Haskins JA, Lechleider RJ, Kreitman J. Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res 17: 5858-5866, 2011.
3. Eremina V, Jefferson A, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358: 1129-1136, 2008.
4. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: result of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 5: 31-41, 2007.
5. Sakai M, Ikezoe T, Bandobashi K, Togitani K, Yokoyama A. Successful treatment of transplantation-associated thrombotic microangiopathy with recombinant human soluble thrombomodulin. Bone Marrow Transplant 45: 803-805, 2010.
6. Sakai M, Ikezoe T, Bandobashi K, Yokoyama A. Successful treatment of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus with recombinant human soluble thrombomodulin. Thromb Res 126: e392-e393, 2010.
7. Fujimura Y, Matsumoto M. Registry of 919 patients with throm botic microangiopathies across Japan: database of Nara Medical University during 1998-2008. Intern Med 49: 7-15, 2010.
8. Elliott MA, Letendre L, Gastineau DA, Winters JL, Pruthi RK, Heit JA. Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration. Eur J Haematol 85: 43-50, 2010.
9. Gando S, Iba T, Eguchi Y, et al; Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteris. Crit Care Med 34: 625-631, 2006.
10. Zupancic M, Shah PC, Shah-Khan F. Gemcitabine-associated thrombotic thrombocytopenic purpura. Lancet Oncol 8: 634-641, 2007.
11. Conway EM. Thrombomodulin and its role in inflammation. Semin Immunopathol 34: 107-125, 2012.
12. Feldman DR, Baum MS, Ginsberg MS, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 1432-1439, 2009.
13. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 27: 1227-1234, 2009.
14. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the cancer and leukemia group B (CALGB 80303). J Clin Oncol 28: 3617-3622, 2010.
15. Humphreys BD, Sharman JP, Henderson JM, et al. Gemcitabineassociated thrombotic microangiopathy. Cancer 100: 2664-2670, 2004.
16. Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of sunitinib activity. Ann Oncol 18: 1117, 2007.
17. Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 20: 807-815, 2009.